Lymph node metastases and elevated postoperative calcitonin: Predictors of poor survival in medullary thyroid carcinoma
Päivi Siironen, Jaana Hagström, Hanna O Mäenpää et al. · Acta Oncologica · 2015
Background Total thyroidectomy is the treatment of choice for medullary thyroid carcinoma (MTC), but the extent of neck dissection is controversial. Lymph node metastases, distant metastases, and old age are known predictors of poor survival. Patients Patients treated for primary MTC at Helsinki University Hospital from 1990 to 2009 were included (n = 54). Their clinical characteristics, treatment, and outcome were analysed retrospectively, these patients were followed until death or their last follow-up date. Results At last follow-up (3.4-23 years), of 54 MTC patients, 19 (35%) were disease-free, 17 (32%) were alive with disease, and 12 (22%) had died of MTC; six patients died of unrelated causes (11%). All disease-free patients were node negative and had normal postoperative calcitonin level. Of 19 disease-free patients, only four (21%) had undergone lymph node dissection. All patients who died of MTC were Stage IV at diagnosis and died with distant metastases. Disease-specific five-and 10-year survival was 84% and 76.2%. Advanced T-stage (p = 0.004), lymph node metastases (p < 0.001), distant metastases (p < 0.001), stage (p < 0.001), and elevated postoperative calcitonin (p < 0.001) significantly associated with survival. Conclusions Lymph node metastasis and elevated postoperative calcitonin are important prognostic factors. Patients with lymph node metastasis and/or elevated postoperative calcitonin with present treatments cannot become disease-free, but most of them can live a long life with metastasis.
Cited by 33 works. doi:10.3109/0284186x.2015.1070963 Open-access PDF
Authors
References
- TNM Classification of Malignant Tumours
- Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
- Medullary thyroid carcinoma
- Impact of Routine Measurement of Serum Calcitonin on the Diagnosis and Outcome of Medullary Thyroid Cancer: Experience in 10,864 Patients with Nodular Thyroid Disorders
- Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients
- Prognosis of medullary thyroid carcinoma
- Long-term Course of Patients with Persistent Hypercalcitoninemia After Apparent Curative Primary Surgery for Medullary Thyroid Carcinoma
- Patterns of Nodal Metastases in Palpable Medullary Thyroid Carcinoma
- Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation